Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 15;21(1):913.
doi: 10.1186/s12967-023-04759-3.

EZH1/2 alteration as a potential biomarker for immune checkpoint inhibitors across multiple cancer types

Huageng Huang #  1 , Xinyi Deng #  2 , Le Yu #  3 , He Huang  1 , Zhao Wang  1 , Huangming Hong  4 , Tongyu Lin  5   6
Affiliations

EZH1/2 alteration as a potential biomarker for immune checkpoint inhibitors across multiple cancer types

Huageng Huang et al. J Transl Med. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Prevalence of EZH1/2 alteration in 65,853 patients with different cancer types. CNS indicates the central nervous system
Fig. 2
Fig. 2
The role of EZH1/2 alteration in ICI therapy. Kaplan–Meier survival analysis comparing overall survival between EZH1/2 alteration and wild-type patients in the ICI treatment, A discovery cohort and B validation cohort. Kaplan–Meier survival analysis comparing, C overall survival and D progression-free survival between EZH1/2 alteration and wild-type patients in the non-ICI treatment cohort. Comparison of the TMB between the EZH1/2 alteration and wild-type groups in the ICI treatment, E discovery and F validation cohorts and G non-ICI treatment cohort. H Comparison of alteration event frequency associated with DDR pathway between EZH1/2 alteration and wild-type patients in the TCGA pan‑cancer cohort. ICI, immune checkpoint inhibitor; HR, hazard ratio; CI, confidence interval; TMB, tumor mutation burden; FA, Fanconi anemia; HRR, homologous recombination repair; NHEJ, nonhomologous end-joining; BER, base excision repair; DR, direct repair; MMR, mismatch repair; NER, nucleotide excision repair; TLS, translesion synthesis; DDR, DNA damage response; TCGA, The Cancer Genome Atlas
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186:1652–1669. doi: 10.1016/j.cell.2023.03.006. - DOI - PubMed
    1. Pang K, Shi ZD, Wei LY, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug Resist Updat. 2023;66:100907. doi: 10.1016/j.drup.2022.100907. - DOI - PubMed
    1. Wassef M, Luscan A, Aflaki S, et al. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer. Proc Natl Acad Sci USA. 2019;116:6075–6080. doi: 10.1073/pnas.1814634116. - DOI - PMC - PubMed
    1. Donaldson-Collier MC, Sungalee S, Zufferey M, et al. EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains. Nat Genet. 2019;51:517–528. doi: 10.1038/s41588-018-0338-y. - DOI - PubMed
    1. Eich ML, Athar M, Ferguson JE, 3rd, Varambally S. EZH2-targeted therapies in cancer: hype or a reality. Cancer Res. 2020;80:5449–5458. doi: 10.1158/0008-5472.CAN-20-2147. - DOI - PMC - PubMed

Publication types